Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
cilta-cel
Description:
Cilta-cel is a B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy used to treat relapsed or refractory multiple myeloma.
Primary topic:
CAR-T cell therapy research (61%)
Related topics:
CAR-T cell therapy research (61%),
Multiple Myeloma Research and Treatments (32%)
OpenAlex ID:
keywords/cilta-cel
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
2023
·
Jesús San-Miguel
, Binod Dhakal
, et al.
·
New England Journal of Medicine
·
950
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
2022
·
Adam D. Cohen
, María-Victoria Mateos
, et al.
·
Blood
·
238
PDF
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
2022
·
Endeshaw Chekol Abebe
, Mestet Yibeltal Shiferaw
, et al.
·
Frontiers in Immunology
·
133
PDF
Current state and next-generation CAR-T cells in multiple myeloma
2022
·
Salomon Manier
, Tiziano Ingegnere
, et al.
·
Blood Reviews
·
123
PDF
CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma
2023
·
Simon J. Harrison
, Tamia Nguyen
, et al.
·
Blood
·
108
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
2020
·
Deepu Madduri
, Jesus G. Berdeja
, et al.
·
Blood
·
96
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
2025
·
Simon J. Harrison
, Cyrille Touzeau
, et al.
·
New England Journal of Medicine
·
80
Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma
2021
·
Rahul Banerjee
, Jeffrey Marsal
, et al.
·
Transplantation and Cellular Therapy
·
60
Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)
2021
·
Dominik Dytfeld
, Binod Dhakal
, et al.
·
Blood
·
54
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
2025
·
Binod Dhakal
, Othman S. Akhtar
, et al.
·
Blood
·
50
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
2021
·
Luciano J. Costa
, Yi Lin
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
47
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
2023
·
Doris K. Hansen
, Krina K. Patel
, et al.
·
Journal of Clinical Oncology
·
45
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma
2023
·
Sundar Jagannath
, Nedra Joseph
, et al.
·
Oncology and Therapy
·
42
PDF
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
2022
·
Niels WCJ Van De Donk
, Mounzer Agha
, et al.
·
Blood
·
31
Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
2022
·
Santiago Thibaud
, Md. Babu Mia
, et al.
·
Blood
·
29
Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
2023
·
Saurav Das
, Sikander Ailawadhi
, et al.
·
Current Oncology
·
28
PDF
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
2025
·
Maximilian J. Steinhardt
, Christoph Schaefers
, et al.
·
Blood Cancer Journal
·
27
PDF
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
2021
·
Katja Weisel
, Thomas Martin
, et al.
·
Clinical Drug Investigation
·
27
PDF
DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
2022
·
Mario Boccadoro
, Jesús San-Miguel
, et al.
·
Blood
·
26
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
2024
·
Andrew J. Yee
·
Blood Cancer Journal
·
23
CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy
2021
·
Niels W.C.J. Van de Donk
, Michel Delforge
, et al.
·
Blood
·
23
Updates on CAR T cell therapy in multiple myeloma
2024
·
Fatemeh Nasiri
, Yasaman Asaadi
, et al.
·
Biomarker Research
·
22
PDF
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study
2022
·
Adam D. Cohen
, Parameswaran Hari
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
22
Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
2024
·
Omar Nadeem
, Sarah Nikiforow
, et al.
·
Blood
·
21
PDF
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
2023
·
Thomas G Martin
, Deepu Madduri
, et al.
·
Future Oncology
·
21
Show more works
View as search
Works count:
299
Citation count:
2,897
Year
Topic
Type